Ireland's Priothera Raises €30m For Mocravimod in AML
Compound Been Tested In Autoimmune Disorders
Novartis passed up the chance for further development of Kyorin's mocravimod for autoimmune diseases but newly formed Priothera is evaluating the S1P receptor modulator for acute myeloid leukemia patients undergoing hematopoietic stem cell transplantation.
